BIOMAT Database Logo BIOMAT Database Logo

Donor lymphocyte infusion for late relapse followed by kidney transplantation for end-stage renal failure after allogeneic bone marrow transplantation for chronic myeloid leukemia. 2003

Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D015464 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. Granulocytic Leukemia, Chronic,Leukemia, Granulocytic, Chronic,Leukemia, Myelocytic, Chronic,Leukemia, Myelogenous, Chronic,Leukemia, Myeloid, Chronic,Myelocytic Leukemia, Chronic,Myelogenous Leukemia, Chronic,Myeloid Leukemia, Chronic,Leukemia, Chronic Myelogenous,Leukemia, Chronic Myeloid,Leukemia, Myelogenous, Ph1 Positive,Leukemia, Myelogenous, Ph1-Positive,Leukemia, Myeloid, Ph1 Positive,Leukemia, Myeloid, Ph1-Positive,Leukemia, Myeloid, Philadelphia Positive,Leukemia, Myeloid, Philadelphia-Positive,Myelogenous Leukemia, Ph1-Positive,Myeloid Leukemia, Ph1-Positive,Myeloid Leukemia, Philadelphia-Positive,Chronic Granulocytic Leukemia,Chronic Granulocytic Leukemias,Chronic Myelocytic Leukemia,Chronic Myelocytic Leukemias,Chronic Myelogenous Leukemia,Chronic Myelogenous Leukemias,Chronic Myeloid Leukemia,Chronic Myeloid Leukemias,Granulocytic Leukemias, Chronic,Leukemia, Chronic Granulocytic,Leukemia, Chronic Myelocytic,Leukemia, Ph1-Positive Myelogenous,Leukemia, Ph1-Positive Myeloid,Leukemia, Philadelphia-Positive Myeloid,Leukemias, Chronic Granulocytic,Leukemias, Chronic Myelocytic,Leukemias, Chronic Myelogenous,Leukemias, Chronic Myeloid,Leukemias, Ph1-Positive Myelogenous,Leukemias, Ph1-Positive Myeloid,Leukemias, Philadelphia-Positive Myeloid,Myelocytic Leukemias, Chronic,Myelogenous Leukemia, Ph1 Positive,Myelogenous Leukemias, Chronic,Myelogenous Leukemias, Ph1-Positive,Myeloid Leukemia, Ph1 Positive,Myeloid Leukemia, Philadelphia Positive,Myeloid Leukemias, Chronic,Myeloid Leukemias, Ph1-Positive,Myeloid Leukemias, Philadelphia-Positive,Ph1-Positive Myelogenous Leukemia,Ph1-Positive Myelogenous Leukemias,Ph1-Positive Myeloid Leukemia,Ph1-Positive Myeloid Leukemias,Philadelphia-Positive Myeloid Leukemia,Philadelphia-Positive Myeloid Leukemias
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal

Related Publications

Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation.
March 1992, Blood,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
[Complete cytogenetic response obtained with unrelated donor lymphocyte infusion for relapse of chronic myeloid leukemia in blastic crisis after allogeneic bone marrow transplantation].
March 2001, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
A mediastinal mass after donor lymphocyte infusion for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
June 2006, Leukemia & lymphoma,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.
March 2004, Bone marrow transplantation,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
Isolated extramedullary relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia.
July 1998, Bone marrow transplantation,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
Chronic myeloid leukemia: management of relapse after allogeneic bone marrow transplantation.
June 1993, Leukemia & lymphoma,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
Donor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation.
June 1999, Bone marrow transplantation,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
September 2009, Leukemia research,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
December 1995, Blood,
Stéphanie Humblet-Baron, and Frédéric Baron, and Yves Beguin, and Alfred Chachati, and Jean Bury, and Emmanuel Morelon, and Henri Kreis
Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
March 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!